tiprankstipranks
Zenas BioPharma completed targeted enrollment of Phase 3 INDIGO trial
The Fly

Zenas BioPharma completed targeted enrollment of Phase 3 INDIGO trial

Zenas BioPharma (ZBIO) announced the completion of its targeted enrollment for the Phase 3 INDIGO trial of its lead product candidate, obexelimab, for the treatment of patients with IgG4-RD. “With the completion of targeted enrollment in our INDIGO trial, the largest IgG4-RD clinical trial ever conducted, Zenas has demonstrated its capabilities to execute on our expansive clinical development plans for obexelimab,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas. “Importantly, we expect to report topline results by the end of next year and advance the Company toward our goal of becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need.”

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App